Pharma Business review is using cookies

ContinueLearn More
Close
August 14, 2018

Izana begins phase II proof-of-concept study of spinal arthritis drug

UK-based biopharmaceutical company Izana Bioscience has commenced a phase II proof-of-concept clinical study of namilumab in ankylosing spondylitis.